drug discovery | Biomarker Commons

drug discovery

Roche and Isis Pharmaceuticals Form Alliance for Huntington's Disease

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) recently announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics. In addition, Isis and Roche will be collaborating to combine Isis' ASOs and Roche's proprietary "brain shuttle" program with the objective of increasing the brain penetration of ASOs with systemic administration.


Tags:

QIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological Data

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of Ingenuity Systems, Inc., the leading provider of software solutions to efficiently and accurately analyze and interpret the biological meaning of genomic data.

Ingenuity, a privately-held U.S. company based in California’s Silicon Valley, has created the market leading expertly curated knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems.


Tags:

Crown Bioscience, Inc. and Horizon Discovery Announce Exclusive Two Year Agreement to Offer Combined Solutions for In Vivo Drug Discovery Model Development

Crown Bioscience, Inc. (Crown), a leading global drug discovery and development service company, and Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, recently announced they have signed an exclusive two year collaboration agreement. Under the terms of the agreement Crown will be given access to Horizon’s proprietary collection of X-MAN isogenic cell lines to develop novel in vivo models for drug discovery. 


Tags:

Premium Subscription Required for Access


Tags:

Premium Subscription Required for Access


Tags:

Premium Subscription Required for Access


Tags: